Premature ventricular contraction laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) |
Homa Najafi (talk | contribs) No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Premature ventricular contraction}} | {{Premature ventricular contraction}} | ||
{{CMG}}; {{AE}} {{M.P}} | {{CMG}}; {{AE}}{{Radwa}}{{Homa}} {{M.P}} | ||
==Overview== | ==Overview== | ||
| Line 22: | Line 22: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon" |<nowiki></nowiki>'''1.''' In patients with structural heart disease, measurement of natriuretic peptides (BNP or N-terminal pro-BNP) can be useful by adding prognostic information to standard risk factors for predicting SCD or SCA ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]]).''<ref name="ScottBarry2009">{{cite journal|last1=Scott|first1=Paul A.|last2=Barry|first2=James|last3=Roberts|first3=Paul R.|last4=Morgan|first4=John M.|title=Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis|journal=European Journal of Heart Failure|volume=11|issue=10|year=2009|pages=958–966|issn=13889842|doi=10.1093/eurjhf/hfp123}}</ref><ref name="LevineRosenberg2014">{{cite journal|last1=Levine|first1=Yehoshua C.|last2=Rosenberg|first2=Michael A.|last3=Mittleman|first3=Murray|last4=Samuel|first4=Michelle|last5=Methachittiphan|first5=Nilubon|last6=Link|first6=Mark|last7=Josephson|first7=Mark E.|last8=Buxton|first8=Alfred E.|title=B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias|journal=Heart Rhythm|volume=11|issue=7|year=2014|pages=1109–1116|issn=15475271|doi=10.1016/j.hrthm.2014.04.024}}</ref><ref name="BergerHuelsman2002">{{cite journal|last1=Berger|first1=Rudolf|last2=Huelsman|first2=Martin|last3=Strecker|first3=Karin|last4=Bojic|first4=Anja|last5=Moser|first5=Petra|last6=Stanek|first6=Brigitte|last7=Pacher|first7=Richard|title=B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure|journal=Circulation|volume=105|issue=20|year=2002|pages=2392–2397|issn=0009-7322|doi=10.1161/01.CIR.0000016642.15031.34}}</ref><ref name="AhmadFiuzat2014">{{cite journal|last1=Ahmad|first1=Tariq|last2=Fiuzat|first2=Mona|last3=Neely|first3=Benjamin|last4=Neely|first4=Megan L.|last5=Pencina|first5=Michael J.|last6=Kraus|first6=William E.|last7=Zannad|first7=Faiez|last8=Whellan|first8=David J.|last9=Donahue|first9=Mark P.|last10=Piña|first10=Ileana L.|last11=Adams|first11=Kirkwood F.|last12=Kitzman|first12=Dalane W.|last13=O'Connor|first13=Christopher M.|last14=Felker|first14=G. Michael|title=Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure|journal=JACC: Heart Failure|volume=2|issue=3|year=2014|pages=260–268|issn=22131779|doi=10.1016/j.jchf.2013.12.004}}</ref><nowiki/> | |bgcolor="LemonChiffon" |<nowiki></nowiki>'''1.''' In [[patients]] with [[structural heart disease]], measurement of [[natriuretic peptides]] ([[Brain natriuretic peptide|BNP]] or [[N-terminal pro-BNP]]) can be useful by adding [[prognostic]] information to standard [[risk factors]] for predicting [[SCD]] or [[Sudden cardiac arrest|SCA]] ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]]).''<ref name="ScottBarry2009">{{cite journal|last1=Scott|first1=Paul A.|last2=Barry|first2=James|last3=Roberts|first3=Paul R.|last4=Morgan|first4=John M.|title=Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis|journal=European Journal of Heart Failure|volume=11|issue=10|year=2009|pages=958–966|issn=13889842|doi=10.1093/eurjhf/hfp123}}</ref><ref name="LevineRosenberg2014">{{cite journal|last1=Levine|first1=Yehoshua C.|last2=Rosenberg|first2=Michael A.|last3=Mittleman|first3=Murray|last4=Samuel|first4=Michelle|last5=Methachittiphan|first5=Nilubon|last6=Link|first6=Mark|last7=Josephson|first7=Mark E.|last8=Buxton|first8=Alfred E.|title=B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias|journal=Heart Rhythm|volume=11|issue=7|year=2014|pages=1109–1116|issn=15475271|doi=10.1016/j.hrthm.2014.04.024}}</ref><ref name="BergerHuelsman2002">{{cite journal|last1=Berger|first1=Rudolf|last2=Huelsman|first2=Martin|last3=Strecker|first3=Karin|last4=Bojic|first4=Anja|last5=Moser|first5=Petra|last6=Stanek|first6=Brigitte|last7=Pacher|first7=Richard|title=B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure|journal=Circulation|volume=105|issue=20|year=2002|pages=2392–2397|issn=0009-7322|doi=10.1161/01.CIR.0000016642.15031.34}}</ref><ref name="AhmadFiuzat2014">{{cite journal|last1=Ahmad|first1=Tariq|last2=Fiuzat|first2=Mona|last3=Neely|first3=Benjamin|last4=Neely|first4=Megan L.|last5=Pencina|first5=Michael J.|last6=Kraus|first6=William E.|last7=Zannad|first7=Faiez|last8=Whellan|first8=David J.|last9=Donahue|first9=Mark P.|last10=Piña|first10=Ileana L.|last11=Adams|first11=Kirkwood F.|last12=Kitzman|first12=Dalane W.|last13=O'Connor|first13=Christopher M.|last14=Felker|first14=G. Michael|title=Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure|journal=JACC: Heart Failure|volume=2|issue=3|year=2014|pages=260–268|issn=22131779|doi=10.1016/j.jchf.2013.12.004}}</ref><nowiki/> | ||
|- | |||
|} | |||
===Recommendation for Genetic Counselling=== | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki></nowiki>'''1.''' In [[patients]] and family members in whom [[genetic testing]] for [[Risk stratification tools|risk stratification]] for [[Sudden cardiac arrest|SCA]] or [[Sudden cardiac death|SCD]] is recommended, [[genetic counseling]] | |||
is beneficial. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C-EO]])''. | |||
|- | |- | ||
|} | |} | ||
Latest revision as of 03:18, 15 July 2020
|
Premature ventricular contraction Microchapters |
|
Differentiating Premature Ventricular Contraction from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Premature ventricular contraction laboratory findings On the Web |
|
FDA on Premature ventricular contraction laboratory findings |
|
Premature ventricular contraction laboratory findings in the news |
|
Blogs on Premature ventricular contraction laboratory findings |
|
to Hospitals Treating Premature ventricular contraction laboratory findings |
|
Risk calculators and risk factors for Premature ventricular contraction laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Radwa AbdElHaras Mohamed AbouZaied, M.B.B.S[2] Homa Najafi, M.D.[3] Mugilan Poongkunran M.B.B.S [4]
Overview
Many cases of premature ventricular contraction have no definite cause, it may be the result of various other problems. If PVC patients present with symptoms, a generalized approach is done to find the precipitating factors.
Laboratory Findings
The following investigations are done to patients with symptoms :
- Renal function and electrolytes
- Complete blood count
- ABG : To rule out hypercapnia and hypoxia.
- Thyroid-stimulating hormone : To rule out hyperthyroidism and of relevance if amiodarone is administered for treatment.
2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT)[1]
Recommendation for Biomarkers
| Class IIa |
| 1. In patients with structural heart disease, measurement of natriuretic peptides (BNP or N-terminal pro-BNP) can be useful by adding prognostic information to standard risk factors for predicting SCD or SCA (Level of Evidence: B-NR).[2][3][4][5] |
Recommendation for Genetic Counselling
| Class I |
| 1. In patients and family members in whom genetic testing for risk stratification for SCA or SCD is recommended, genetic counseling
is beneficial. (Level of Evidence: C-EO). |
References
- ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.
- ↑ Scott, Paul A.; Barry, James; Roberts, Paul R.; Morgan, John M. (2009). "Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis". European Journal of Heart Failure. 11 (10): 958–966. doi:10.1093/eurjhf/hfp123. ISSN 1388-9842.
- ↑ Levine, Yehoshua C.; Rosenberg, Michael A.; Mittleman, Murray; Samuel, Michelle; Methachittiphan, Nilubon; Link, Mark; Josephson, Mark E.; Buxton, Alfred E. (2014). "B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias". Heart Rhythm. 11 (7): 1109–1116. doi:10.1016/j.hrthm.2014.04.024. ISSN 1547-5271.
- ↑ Berger, Rudolf; Huelsman, Martin; Strecker, Karin; Bojic, Anja; Moser, Petra; Stanek, Brigitte; Pacher, Richard (2002). "B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure". Circulation. 105 (20): 2392–2397. doi:10.1161/01.CIR.0000016642.15031.34. ISSN 0009-7322.
- ↑ Ahmad, Tariq; Fiuzat, Mona; Neely, Benjamin; Neely, Megan L.; Pencina, Michael J.; Kraus, William E.; Zannad, Faiez; Whellan, David J.; Donahue, Mark P.; Piña, Ileana L.; Adams, Kirkwood F.; Kitzman, Dalane W.; O'Connor, Christopher M.; Felker, G. Michael (2014). "Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure". JACC: Heart Failure. 2 (3): 260–268. doi:10.1016/j.jchf.2013.12.004. ISSN 2213-1779.